GLOW/KLOW for InjuriesThe Wrong Ratios

Pre-mixed GLOW and KLOW peptide blends are popular—but their ratios are optimized for skincare, not injury recovery. GLOW contains three peptides (GHK-Cu, BPC-157, TB-4). KLOW adds a fourth: KPV, an anti-inflammatory tripeptide. Both share the same base ratio, and neither is formulated for structural repair.

If you're trying to heal a tendon, ligament, or soft tissue injury with either blend, you're using the wrong tool for the job—even KLOW, which is closer because it includes KPV.

This guide explains why those ratios fail for structural repair, and presents the correct protocol: BPC-157, TB-500, GHK-Cu, and KPV—four peptides at injury-appropriate doses—plus NAD+ as the metabolic fuel that makes the whole system work.

GLOW vs KLOW: What's Actually in Them

First, the distinction matters:

• GLOW = GHK-Cu 50 mg / BPC-157 10 mg / TB-4 10 mg (three peptides)
• KLOW = GHK-Cu 50 mg / BPC-157 10 mg / TB-4 10 mg / KPV 10 mg (four peptides)

The only difference is KPV — an anti-inflammatory tripeptide that blocks the cell's master inflammatory switch. KLOW includes it; GLOW doesn't. Both use the same 50/10/10 base ratio designed for cosmetic applications — facial rejuvenation, skin quality, hair growth. GHK-Cu dominates because it drives collagen gene expression in skin.

One more distinction that matters for this protocol: GLOW and KLOW contain full-length thymosin beta-4 (TB-4) — the 43-amino-acid protein used for skin and systemic regeneration. The injury protocol below calls for TB-500 — the 17–23 fragment of thymosin beta-4, a smaller molecule with higher per-mg potency for acute cell migration and tissue repair. They are not interchangeable at injury doses. (Note: most commercial "TB-500" is actually mislabeled TB-4 — always verify via third-party CoA before purchasing. More on this below.)

For injury recovery, these ratios are backwards.

Result: People use GLOW or KLOW for injuries, get minimal structural repair, and conclude "peptides don't work." The peptides work—the ratios don't. KLOW is closer (it has KPV), but the core repair peptides are still underdosed by 80–90%.

The Correct Ratios for Injury Healing

NAD+ is not a peptide—it's a coenzyme that powers the metabolic machinery. Without adequate NAD+, repair cells have the instructions but lack the energy to execute them. It's the fuel that makes the four peptides work.

Cycle length: 8–12 weeks

Why These Blends Fail for Injuries

The Ratio Problem

In a typical GLOW or KLOW blend (50/10/10 base), if you inject 0.5 mL daily:

• You get ~2.5 mg GHK-Cu (reasonable for skin)
• You get ~0.5 mg BPC-157 (1/10th of injury dose)
• You get ~0.5 mg TB-4 (1/8th of injury dose)
• KLOW adds ~0.5 mg KPV (at the low end of therapeutic range)

The repair peptides are underdosed by 80–90%. You're getting a skincare treatment, not an injury protocol. KLOW's inclusion of KPV helps with inflammation, but it can't compensate for critically underdosed BPC-157 and TB-500.

The Missing Piece

Neither blend includes:

• NAD+ — Essential for cellular energy during high-demand tissue reconstruction

And GLOW specifically lacks:

• KPV — Critical for controlling inflammation without suppressing repair

Without adequate energy, repair cells can't do their work. Without inflammation control (GLOW's gap), healing stalls in the inflammatory phase.

When GLOW/KLOW IS Appropriate

KLOW is the better cosmetic choice when inflammation is present (rosacea, post-procedure, reactive skin). But for structural injury repair, neither blend provides therapeutic doses of the compounds that matter most.

The Four Core Peptides

NAD+: The Metabolic Fuel

NAD+ is not a peptide — it's a coenzyme that shuttles energy through every metabolic pathway in the cell. Without it, cells can't convert nutrients into usable energy.

Why Injured Tissue Needs Extra NAD+

During repair, cells are working overtime:

• Fibroblasts synthesizing collagen
• Endothelial cells building new vessels
• Immune cells clearing debris

This increased metabolic demand burns through NAD+ faster than normal. When NAD+ runs low:

• Fat burning for energy stalls (β-oxidation)
• Overall energy production collapses
• Repair cells "brown out" — alive but unable to do their work
• Healing plateaus

What NAD+ Does

NAD+ Is Different

Unlike the four peptides, NAD+:

• Is a naturally occurring coenzyme, not a synthesized peptide
• Works through metabolic pathways, not receptor signaling
• Requires separate injection (acidic; don't mix with peptides)
• Supports the repair process rather than directing it

The peptides provide repair signals. NAD+ provides the metabolic capacity cells need to execute them.

The Synergy Effect

Running all five compounds creates conditions where repair can proceed on multiple fronts simultaneously:

This is why using GLOW or KLOW for injuries fails—even if you use more of it. The ratios prevent these synergies from developing properly. KLOW gets closer (KPV is present), but the BPC-157 and TB-500 underdosing means the vascular and migratory foundations are too weak for the other compounds to build on.

Dosing

The Four Peptides

NAD+ (Separate)

Weight-Based Guidance

• BPC-157: ~6–8 mcg/kg daily
• TB-500: ~0.04–0.06 mg/kg per dose
• GHK-Cu: ~0.02–0.04 mg/kg
• KPV: ~7–12 mcg/kg daily
• NAD+: ~2–3 mg/kg per injection

Weekly Schedule (Example)

Note: NAD+ must be injected separately—it's acidic and can destabilize other peptides.

Timeline: What to Expect

Supporting Factors

When Progress Stalls

1. Check protein, sleep, and hydration. Under-eating stalls repair.
2. Verify injection technique and storage conditions.
3. If tissue is warm but recovery timing is off (poor sleep, random flares) → Tesamorelin
4. If neuropathic symptoms persist (burning, tingling) → ARA-290
5. If you progress then flare under load → SS-31 add-on

Managing Side Effects

Contraindications

Do not use if:

• Active malignancy or proliferative retinopathy (BPC-157, TB-500, GHK-Cu promote angiogenesis)
• Pregnancy or breastfeeding
• Wilson's disease or uncontrolled copper overload (GHK-Cu)

Use with medical supervision if:

• Uncontrolled diabetes or severe cardiovascular disease
• Active autoimmune flare
• Therapeutic anticoagulation
• Recent corticosteroid injections

Sports compliance: TB-500 is prohibited by WADA/USADA.

What Comes Next

After 8–12 weeks, three paths:

Complete: If markers are met (pain ≤2/10, ROM ≥80%, no swelling after activity), taper off. Consider periodic maintenance cycles for chronic injury sites.

Extend: If progress is good but incomplete, continue for another 4–6 weeks.

Add modules: If specific bottlenecks persist:

• Sleep/recovery timing issues → Tesamorelin ± Ipamorelin
• Neuropathic symptoms → ARA-290
• Relapse under load → SS-31

FAQ

Related Topics

• BPC-157 + TB-500 Protocol — Simpler foundational option
• Tesamorelin Guide — includes GH timing and injury recovery section
• ARA-290 Guide — includes nerve pain and injury recovery section
• SS-31 Guide — includes mitochondrial stability section
• NAD+ Guide — Cellular energy deep-dive
• GLOW & KLOW Skincare Protocol — When GLOW/KLOW IS appropriate
• BPC-157 Guide — BPC-157 standalone deep-dive
• TB-500 Guide — TB-500 standalone deep-dive
• GHK-Cu Guide — GHK-Cu standalone deep-dive

References

• BPC-157 review: PMC8275860
• TB-500 dermal repair: PubMed 12581423
• TB-500 fragment context: PMC7822313
• NAD+ metabolism: PMC7963035
• GHK-Cu review: PubMed 29986520
• KPV NF-κB: PubMed 18061177

Educational content only. Some compounds discussed are FDA-approved medications; others are research peptides without FDA approval — not due to safety concerns, but because unpatentable compounds cannot justify the required trial investment. Work with a qualified healthcare provider before using any protocol.